|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SPRED1 |
Gene summary for SPRED1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SPRED1 | Gene ID | 161742 |
| Gene name | sprouty related EVH1 domain containing 1 | |
| Gene Alias | LGSS | |
| Cytomap | 15q14 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q7Z699 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 161742 | SPRED1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.63e-15 | -5.83e-01 | 0.0155 |
| 161742 | SPRED1 | HTA11_2951_2000001011 | Human | Colorectum | AD | 9.37e-04 | -6.75e-01 | 0.0216 |
| 161742 | SPRED1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 5.62e-04 | -5.18e-01 | -0.1207 |
| 161742 | SPRED1 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.28e-14 | -4.81e-01 | -0.1464 |
| 161742 | SPRED1 | HTA11_866_2000001011 | Human | Colorectum | AD | 2.45e-06 | -3.78e-01 | -0.1001 |
| 161742 | SPRED1 | HTA11_546_2000001011 | Human | Colorectum | AD | 1.12e-03 | -5.72e-01 | -0.0842 |
| 161742 | SPRED1 | HTA11_866_3004761011 | Human | Colorectum | AD | 3.40e-13 | -5.81e-01 | 0.096 |
| 161742 | SPRED1 | HTA11_10711_2000001011 | Human | Colorectum | AD | 1.47e-06 | -5.50e-01 | 0.0338 |
| 161742 | SPRED1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 6.89e-15 | -4.80e-01 | 0.0674 |
| 161742 | SPRED1 | HTA11_6818_2000001011 | Human | Colorectum | AD | 2.32e-04 | -6.32e-01 | 0.0112 |
| 161742 | SPRED1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 6.88e-17 | -4.73e-01 | 0.3859 |
| 161742 | SPRED1 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 2.50e-04 | -5.80e-01 | 0.2585 |
| 161742 | SPRED1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.30e-22 | -5.66e-01 | 0.3005 |
| 161742 | SPRED1 | F007 | Human | Colorectum | FAP | 5.87e-07 | -4.92e-01 | 0.1176 |
| 161742 | SPRED1 | A001-C-207 | Human | Colorectum | FAP | 7.23e-03 | 2.20e-01 | 0.1278 |
| 161742 | SPRED1 | A015-C-203 | Human | Colorectum | FAP | 2.79e-28 | -4.94e-01 | -0.1294 |
| 161742 | SPRED1 | A015-C-204 | Human | Colorectum | FAP | 9.98e-04 | -3.03e-01 | -0.0228 |
| 161742 | SPRED1 | A014-C-040 | Human | Colorectum | FAP | 6.36e-03 | -4.02e-01 | -0.1184 |
| 161742 | SPRED1 | A002-C-201 | Human | Colorectum | FAP | 1.85e-06 | -2.45e-01 | 0.0324 |
| 161742 | SPRED1 | A001-C-119 | Human | Colorectum | FAP | 1.97e-11 | -5.70e-01 | -0.1557 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004001313 | Prostate | Tumor | negative regulation of locomotion | 94/3246 | 391/18723 | 4.20e-04 | 3.21e-03 | 94 |
| GO:00107171 | Prostate | Tumor | regulation of epithelial to mesenchymal transition | 31/3246 | 99/18723 | 4.74e-04 | 3.54e-03 | 31 |
| GO:003033613 | Prostate | Tumor | negative regulation of cell migration | 84/3246 | 344/18723 | 4.95e-04 | 3.66e-03 | 84 |
| GO:003560112 | Prostate | Tumor | protein deacylation | 33/3246 | 112/18723 | 1.05e-03 | 6.77e-03 | 33 |
| GO:00902871 | Prostate | Tumor | regulation of cellular response to growth factor stimulus | 74/3246 | 304/18723 | 1.13e-03 | 7.22e-03 | 74 |
| GO:000647612 | Prostate | Tumor | protein deacetylation | 30/3246 | 101/18723 | 1.50e-03 | 9.27e-03 | 30 |
| GO:009873211 | Prostate | Tumor | macromolecule deacylation | 33/3246 | 116/18723 | 2.00e-03 | 1.16e-02 | 33 |
| GO:007037312 | Prostate | Tumor | negative regulation of ERK1 and ERK2 cascade | 24/3246 | 78/18723 | 2.56e-03 | 1.42e-02 | 24 |
| GO:00308571 | Prostate | Tumor | negative regulation of epithelial cell differentiation | 17/3246 | 49/18723 | 2.61e-03 | 1.43e-02 | 17 |
| GO:00108011 | Prostate | Tumor | negative regulation of peptidyl-threonine phosphorylation | 9/3246 | 20/18723 | 3.73e-03 | 1.91e-02 | 9 |
| GO:007037113 | Prostate | Tumor | ERK1 and ERK2 cascade | 76/3246 | 330/18723 | 4.66e-03 | 2.29e-02 | 76 |
| GO:009009212 | Prostate | Tumor | regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 61/3246 | 256/18723 | 4.84e-03 | 2.37e-02 | 61 |
| GO:00703061 | Prostate | Tumor | lens fiber cell differentiation | 13/3246 | 36/18723 | 5.47e-03 | 2.60e-02 | 13 |
| GO:190134212 | Prostate | Tumor | regulation of vasculature development | 79/3246 | 348/18723 | 5.84e-03 | 2.71e-02 | 79 |
| GO:004353412 | Prostate | Tumor | blood vessel endothelial cell migration | 44/3246 | 176/18723 | 6.27e-03 | 2.89e-02 | 44 |
| GO:004576512 | Prostate | Tumor | regulation of angiogenesis | 77/3246 | 342/18723 | 7.92e-03 | 3.52e-02 | 77 |
| GO:00305122 | Prostate | Tumor | negative regulation of transforming growth factor beta receptor signaling pathway | 23/3246 | 81/18723 | 9.13e-03 | 3.93e-02 | 23 |
| GO:00016541 | Prostate | Tumor | eye development | 82/3246 | 371/18723 | 1.02e-02 | 4.27e-02 | 82 |
| GO:0010799 | Prostate | Tumor | regulation of peptidyl-threonine phosphorylation | 15/3246 | 47/18723 | 1.07e-02 | 4.45e-02 | 15 |
| GO:200102212 | Prostate | Tumor | positive regulation of response to DNA damage stimulus | 28/3246 | 105/18723 | 1.08e-02 | 4.47e-02 | 28 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SPRED1 | SNV | Missense_Mutation | c.337N>A | p.Asp113Asn | p.D113N | Q7Z699 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A18H-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR | |
| SPRED1 | SNV | Missense_Mutation | c.279G>C | p.Lys93Asn | p.K93N | Q7Z699 | protein_coding | deleterious(0.02) | probably_damaging(0.957) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR | |
| SPRED1 | SNV | Missense_Mutation | novel | c.140N>C | p.Val47Ala | p.V47A | Q7Z699 | protein_coding | tolerated(0.12) | benign(0.014) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
| SPRED1 | SNV | Missense_Mutation | c.970A>G | p.Lys324Glu | p.K324E | Q7Z699 | protein_coding | tolerated(0.12) | benign(0.444) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SPRED1 | SNV | Missense_Mutation | novel | c.506N>C | p.Arg169Thr | p.R169T | Q7Z699 | protein_coding | tolerated(0.5) | benign(0.057) | TCGA-GI-A2C9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | SD | |
| SPRED1 | SNV | Missense_Mutation | rs200142785 | c.565N>A | p.Gln189Lys | p.Q189K | Q7Z699 | protein_coding | tolerated(0.69) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SPRED1 | SNV | Missense_Mutation | novel | c.752N>A | p.Arg251Gln | p.R251Q | Q7Z699 | protein_coding | deleterious(0.03) | probably_damaging(0.992) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SPRED1 | SNV | Missense_Mutation | c.397N>A | p.Glu133Lys | p.E133K | Q7Z699 | protein_coding | deleterious(0.03) | benign(0.036) | TCGA-FU-A40J-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | carboplatin | CR | |
| SPRED1 | SNV | Missense_Mutation | novel | c.1175N>T | p.Ser392Leu | p.S392L | Q7Z699 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| SPRED1 | SNV | Missense_Mutation | novel | c.161N>A | p.Gly54Asp | p.G54D | Q7Z699 | protein_coding | deleterious(0.02) | benign(0.089) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |